The Parnassus Endeavor Fund (Trades, Portfolio) sold shares of the following stocks during the second quarter.
The Mattel Inc. (MAT) stake was closed. The trade had an impact of -6.73% on the portfolio.
The manufacturer and marketer of toy products has a market cap of $4.14 billion and an enterprise value of $6.62 billion.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. The return on equity of -57.62% and return on assets of -7.71% are underperforming 100% of companies in the Travel and Leisure industry. Its financial strength is rated 4.2 out of 10. The cash-debt ratio of 0.13 is below the industry median of 0.53.
The largest guru shareholder of the company is PRIMECAP Management (Trades, Portfolio) with 14.72% of outstanding shares, followed by Dodge & Cox with 10.72% and Mason Hawkins (Trades, Portfolio)’ Southeastern Asset Management with 10.38%.
The fund reduced its Alphabet Inc. (GOOGL) position by 60%. The portfolio was impacted by -2.53%.
The holding company with Google as main asset has a market cap of $785 billion and an enterprise value of $675 billion.
GuruFocus gives the company a profitability and growth rating of 9 out of 10. The return on equity of 16.39% and return on assets of 12.52% are outperforming 73% of companies in the Online Media industry. Its financial strength is rated 8.6 out of 10. The cash-debt ratio of 27.91 is above the industry median of 4.88.
The largest guru shareholder of the company is PRIMECAP Management (Trades, Portfolio) with 0.32% of outstanding shares, followed by Ken Fisher (Trades, Portfolio) with 0.20% and Frank Sands (Trades, Portfolio) with 0.16%.
The fund exited its Celgene Corp. (CELG) position. The portfolio was impacted by -2.25%.
The biopharmaceutical firm has a market cap of $63.61 billion and an enterprise value of $76.20 billion.
GuruFocus gives the company a profitability and growth rating of 9 out of 10. The return on equity of 85.38% and return on assets of 13.53% are outperforming 88% of companies in the Drug Manufacturers industry. Its financial strength is rated 5.4 out of 10. The cash-debt ratio of 0.38 is below the industry median of 1.49.
The company's largest guru shareholder is David Abrams (Trades, Portfolio) with 0.96% of outstanding shares, followed by Simons’ Renaissance Technologies with 0.68% and Seth Klarman (Trades, Portfolio)’s Baupost Group with 0.57%.
The guru curbed its Cummins Corp. (CMI) holding by 35.17%, impacting the portfolio by -2.21%.
The seller of enterprise IT solutions has a market cap of $193 billion and an enterprise value of $212 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 34.52% and return on assets of 9.19% are underperforming 77% of companies in the Application Software industry. Its financial strength is rated 5.3 out of 10. The cash-debt ratio of 0.67 is below the industry median of 3.47.
The company's largest guru shareholder is Hotchkis & Wiley with 2.09% of outstanding shares, followed by First Eagle Investment (Trades, Portfolio) with 1.68% and Bill Nygren (Trades, Portfolio)’s Oakmark Fund with 1.09%.
The guru reduced its American Express Co. (AXP) holding by 49.46%, impacting the portfolio by -1.99%.
The provider of charges services as well as credit card services has a market cap of $104 billion and an enterprise value of $131 billion.
GuruFocus gives the company a profitability and growth rating of 3 out of 10. While the return on assets of 3.64% is underperforming the sector, the return on equity of 31.49% is outperforming 52% of companies in the Credit Services industry. Its financial strength is rated 3.2 out of 10. The cash-debt ratio of 0.55 is above the industry median of 1.67.
Warren Buffett (Trades, Portfolio)’s Berkshire Hathaway is the largest guru shareholder of the company with 18.16% of outstanding shares, followed by the Dodge & Cox with 2.82% and Barrow, Hanley, Mewhinney & Strauss with 1.32%.
The guru reduced its AbbVie Inc. (ABBV) holding by 48.24%, impacting the portfolio by -1.76%.
The drug manufacturer has a market cap of $101 billion and an enterprise value of $133 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on assets of 8.55% is outperforming 58% of companies in the Drug Manufacturer industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.14 is below the industry median of 1.49.
Pioneer Investments (Trades, Portfolio) is the company’s largest guru shareholder with 0.26% of outstanding shares, followed by Simons’ firm with 0.17% and Parnassus Endeavor Fund (Trades, Portfolio) with 0.06%.
Disclosure: I do not own any stocks mentioned.
Also check out:
